All News
Filter News
Found 808,690 articles
-
Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress
10/24/2023
Genascence Corporation announced that data from the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis demonstrated that it was safe and well tolerated.
-
Pharmatech Associates Showcases Strategic Program Development for Drug Sponsors and Innovators at CPHI Barcelona 2023
10/24/2023
This week at CPHI Barcelona, Pharmatech Associates will showcase its expertise and capabilities that help global pharmaceutical and emerging biotech companies accelerate their innovation and speed delivery of breakthrough medicines and therapies to patients.
-
Biogennix Launches OsteoSPAN Fiber Matrix
10/24/2023
Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, announced the launch of its new OsteoSPAN Fiber Matrix.
-
KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference
10/24/2023
KalVista Pharmaceuticals, Inc. announced the presentation of a novel analysis characterizing hereditary angioedema attacks occurring in patients receiving long-term prophylaxis treatments at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference in Singapore.
-
LEQEMBI® (lecanemab-irmb) Named One of Time's Best Inventions of 2023
10/24/2023
Eisai Inc. and Biogen Inc. are honored to announce that TIME has selected LEQEMBI® as one of the Best Inventions of 2023 in the Medical Care category.
-
Owens & Minor Announces Third Quarter 2023 Earnings Release Date and Conference Call
10/24/2023
Owens & Minor, Inc. plans to release financial results for the third quarter of 2023 on Friday, November 3, 2023, before trading begins on the New York Stock Exchange.
-
ARTHEx Biotech Announces Sponsorship and Participation in the Spanish Meeting on Oligonucleotide Therapeutics (SMOT III)
10/24/2023
ARTHEx Biotech S.L. announced that it will participate in the Spanish Meeting on Oligonucleotide Therapeutics, taking place October 26-27, 2023, at the Faculty of Pharmacy of the University of Valencia.
-
Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Selective Anchored Immunotherapy Agent, ANK-101, into Human Trials in Solid Tumors
10/24/2023
Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Selective Anchored Immunotherapy Agent, ANK-101, into Human Trials in Solid Tumors.
-
908 Devices Awarded $10.4M Order from the United States Air Force for its Handheld MX908 Device
10/24/2023
908 Devices Inc. announces that it has been awarded a total of $10.4 million in purchase orders from the United States Air Force and Air National Guard Fire & Emergency Services Program for its MX908 handheld mass spectrometry device with Aero module.
-
LumaCyte Launches New Compact Radiance® Instrument for Advanced Therapy Biomanufacturing & QC Environments
10/24/2023
LumaCyte is proud to announce the launch of their newly redesigned flagship Radiance® instrument to meet growing demand for Laser Force Cytology™ precision analytics in space-constrained biomanufacturing facilities.
-
Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor
10/24/2023
Scorpion Therapeutics, Inc. today announced the appointment of Jeff Albers as a strategic advisor to the company.
-
Life Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Radiopharmaceutical Neuraceq® in China
10/24/2023
Life Molecular Imaging and Sinotau Pharmaceutical Group are pleased to announce Neuraceq® has received regulatory approval from National Medical Products Administration in China.
-
Entrinsic Bioscience Announces Breakthrough Innovation for Next Generation Sports and Recreational Rehydration™ Beverages
10/24/2023
Entrinsic Bioscience has published a ground-breaking clinical study demonstrating the potential for next generation sports and rehydration beverages, powered by its new Ultra-Hydrating HeatDefense™ formula which promotes dual action rapid rehydration with new levels of heat protection during sports, physical exertion and high heat stress.
-
Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada
10/24/2023
Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces it has out-licensed its product candidate atomoxetine oral liquid for the treatment of attention deficit hyperactivity disorder in Canada to Kye Pharmaceuticals.
-
Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis
10/24/2023
Ocean Biomedical, Inc., announced that its Chief Scientist, Jonathan Kurtis MD, PhD has received the prestigious Falk Medical Research Trust Transformational Award to advance a new class of anti-malarial drug candidates.
-
Arcus Biosciences Announces New Employment Inducement Grants - October 24, 2023
10/24/2023
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 4,800 shares of the Company’s common stock at an exercise price per share of $16.18, which was the closing price on October 23, 2023, and restricted stock units to acquire a total of 2,400 shares of the Company’s common stock.
-
Oxular Doses First Patients in OXEYE Phase 2 Clinical Trial of Suprachoroidal OXU-001 as a Long-Acting Treatment for Diabetic Macular Edema
10/24/2023
Oxular Limited today announces that it has begun dosing in its OXEYE Phase 2 clinical trial evaluating the company’s lead product candidate, suprachoroidal OXU-001, for the treatment of diabetic macular edema (DME).
-
Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement
10/24/2023
Elektrofi, Inc. announced that it has entered a multi-target research collaboration and license agreement with Eli Lilly and Company to develop next-generation medicines that can be delivered subcutaneously.
-
Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment
10/24/2023
Endogena Therapeutics Inc., a pioneering biotech company dedicated to revolutionizing regenerative medicine, is proud to announce a significant achievement that holds the promise of transforming lives.
-
ViaDerma Update on Stability Testing, Global Sales Distribution, National Licensing, Nupelo & More
10/24/2023
ViaDerma, Inc. is pleased to announce several new and exciting business updates for current and prospective shareholders, customers, partners, and healthcare providers.